CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) — financial distillation
Annual history (10-K)
Quarterly history (10-Q)
Two headline lines are shown to start. Click any item in a legend to add or remove it — every figure on the chart is one the table below also carries, for the period it names.
In brief, from the full filed history
- Revenue grew from $1.30B (period ending 2008-12-27) to $4.02B (period ending 2025-12-27) — a 6.9% annual pace across 17 year(s) of filed history.
- Net margin expanded from -40.5% to -3.6% over that same span.
- Across 52 tracked quarters, the strongest was $1.06B (quarter ending 2023-07-01) and the weakest was $276.1M (quarter ending 2010-09-25).
Annual — most recent 10-K
| Line | Value | Period ends | Form | Filing |
|---|---|---|---|---|
| Revenue | $4.02B | 2025-12-27 | 10-K | 0001100682-26-000022 |
| Gross profit | $300.0M | 2020-12-26 | 10-K | 0001100682-21-000005 |
| Operating income | $25.2M | 2025-12-27 | 10-K | 0001100682-26-000022 |
| Net income | $-144.3M | 2025-12-27 | 10-K | 0001100682-26-000022 |
| Diluted EPS | $-2.91 | 2025-12-27 | 10-K | 0001100682-26-000022 |
| Total assets | $7.14B | 2025-12-27 | 10-K | 0001100682-26-000022 |
| Total liabilities | $3.92B | 2025-12-27 | 10-K | 0001100682-26-000022 |
| Cash & equivalents | $213.8M | 2025-12-27 | 10-K | 0001100682-26-000022 |
| Operating cash flow | $737.6M | 2025-12-27 | 10-K | 0001100682-26-000022 |
Quarterly — most recent 10-Q
| Line | Value | Period ends | Form | Filing |
|---|---|---|---|---|
| Revenue | $1.00B | 2026-06-27 | 10-Q | 0001100682-26-000118 |
| Operating income | $119.9M | 2026-06-27 | 10-Q | 0001100682-26-000118 |
| Net income | $-1.5M | 2026-06-27 | 10-Q | 0001100682-26-000118 |
| Diluted EPS | $-0.03 | 2026-06-27 | 10-Q | 0001100682-26-000118 |
| Total assets | $7.53B | 2026-06-27 | 10-Q | 0001100682-26-000118 |
| Total liabilities | $4.64B | 2026-06-27 | 10-Q | 0001100682-26-000118 |
| Cash & equivalents | $192.0M | 2026-06-27 | 10-Q | 0001100682-26-000118 |
| Operating cash flow | $41.1M | 2026-03-28 | 10-Q | 0001100682-26-000038 |
Reading
The figures above are taken directly from filings with the U.S. Securities and Exchange Commission. The reading below was generated by a local language model from only those figures; it introduces no numbers of its own. It is not investment advice.
Charles River Laboratories International, Inc. (CRL) operates in the life sciences research sector, with a substantial scale evident from its total assets of $7.53B as of the most recent quarterly filing. The company’s revenue has grown at a 6.9% annual pace over 17 years, reaching $4.02B in the latest annual period ending December 27, 2025. This growth trajectory indicates a steady expansion of its core business operations.
The company’s net margin has improved from -40.5% to -3.6% over the same period, reflecting enhanced profitability despite occasional net losses. Notably, the most recent annual period resulted in a net loss of $144.3M. Investors should monitor the company’s ability to sustain profitability and control costs as it continues to scale its operations.
Quarterly revenue has fluctuated between a high of $1.06B in Q2 2023 and a low of $276.1M in Q3 2010, highlighting the volatility inherent in the research services industry. In the most recent quarter ending June 27, 2026, CRL reported revenue of $1.00B and operating income of $119.9M, demonstrating resilience despite a net loss of $1.5M. Future filings should provide insights into the company’s strategies for managing this volatility and improving its bottom line.
Source: SEC EDGAR company facts for CIK 0001100682 · filings index